<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320176</url>
  </required_header>
  <id_info>
    <org_study_id>MV1-F4-CT1</org_study_id>
    <nct_id>NCT01320176</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Dosage and Safety of Two Intramuscular Injections of an Investigational Clade B HIV Vaccine</brief_title>
  <official_title>An Open-label, Phase I, Dose-escalation and Safety Study of Two Intramuscular Injections of a Dose of 2.9 Log or 4 Log CCID50 of the Recombinant HIV I Clade B Measles Vaccine Vector in Healthy Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Pasteur</source>
  <brief_summary>
    <textblock>
      This study aimed to evaluate the safety and reactogenicity of two intramuscular injections of&#xD;
      two different dosages of an investigational clade B HIV vaccine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence, intensity and relationship to vaccination of solicited local and general adverse events (AEs) except fever</measure>
    <time_frame>14-day follow-up after each vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence, intensity and relationship to vaccination of fever</measure>
    <time_frame>21-day follow-up after each vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence, intensity and relationship to vaccination of unsolicited adverse events (AEs)</measure>
    <time_frame>42-day follow-up after each vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence and relationship to vaccination of any serious AEs (SAEs)</measure>
    <time_frame>During the study period (Month 0-11)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence, intensity and relationship to vaccination of clinically significant abnormal haematology and biochemistry values (grade 3 or 4)</measure>
    <time_frame>During the study period (Month 0-11)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of shedding of recombinant virus</measure>
    <time_frame>During the study period (Month 0-11)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recombinant virus infectivity</measure>
    <time_frame>During the study period (Month 0-11)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-mediated immune response (CMI)</measure>
    <time_frame>At day 0, 7, 14, 28, 91, 98, 112, 266</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humoral immune response to HIV antigens</measure>
    <time_frame>At day 14, 28, 84, 98, 112, 266.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received dose A of the investigational HIV vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received dose B of the investigational HIV vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Investigational HIV vaccine dose A</intervention_name>
    <description>The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Investigational HIV vaccine dose B</intervention_name>
    <description>The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who the investigator believes can and will comply with the requirements of&#xD;
             the protocol (e.g. completion of the diary cards, return for follow-up visits) and are&#xD;
             available for all scheduled visits at the investigational site&#xD;
&#xD;
          2. Adult male and or female subjects between 18 and 27 years old.&#xD;
&#xD;
          3. Proven record of measles vaccination (longer than 5 years)&#xD;
&#xD;
          4. Measles antibodies titre &lt; 350 IU/L or &gt; 750 IU/L measured in the previous study&#xD;
             &quot;CEVAC sero-MV-001&quot;.&#xD;
&#xD;
          5. Healthy subjects as established by medical history and clinical examination before&#xD;
             entering into the study.&#xD;
&#xD;
          6. Confirmed HIV negative based on the absence of antibodies and p24.&#xD;
&#xD;
          7. Negative for Hepatitis B surface (HBs) antigen, anti-hepatitis B core (HBc antibodies)&#xD;
             antibody and anti-Hepatitis C Virus (HCV) antibody&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in another clinical study in the last 6 months in which the subject has&#xD;
             been exposed to an investigational product (pharmaceutical product or placebo or&#xD;
             device) or concurrent participation in another clinical study during the study period.&#xD;
&#xD;
          2. Previous inclusion in an HIV vaccine study.&#xD;
&#xD;
          3. Receipt of any other vaccination 1 month before or planning to receive any vaccination&#xD;
             1 month after each study vaccination&#xD;
&#xD;
          4. Receipt of tuberculin skin test 1 month before or planning to receive a tuberculin&#xD;
             test 1 month after each study vaccination&#xD;
&#xD;
          5. Receipt of allergy treatment with antigen injections 1 month before or planning to&#xD;
             receive allergy treatment with antigen injections 1 month after each study vaccination&#xD;
&#xD;
          6. Receipt of blood products or immunoglobulins within 120 days prior to enrolment.&#xD;
&#xD;
          7. Measles vaccination or booster within the last 5 years as confirmed by medical&#xD;
             history.&#xD;
&#xD;
          8. Subject is pregnant or breastfeeding or intends to become pregnant within 9 months of&#xD;
             enrolling into the study.&#xD;
&#xD;
          9. Subject is of childbearing potential and does not agree to use a medically acceptable&#xD;
             form of contraception for the duration of the study (9 months post the first&#xD;
             investigational HIV vaccination). Medically acceptable forms of contraception include:&#xD;
             Contraceptive Medication, Intrauterine device, Double barrier method (Condom* and&#xD;
             Occlusive cap (diaphragm or cervical/vault caps) with spermicidal&#xD;
             foam/gel/film/cream/suppository.&#xD;
&#xD;
             * A female condom and a male condom should not be used together as friction between&#xD;
             the two can result in either product failing.&#xD;
&#xD;
         10. History of any significant immunodeficient condition.&#xD;
&#xD;
         11. Chronic administration (defined as more than 14 days) of immunosuppressants or other&#xD;
             immune-modifying drugs within the 6 months prior to the first vaccination&#xD;
&#xD;
         12. Individuals who are at high risk of acquired HIV infection as determined by the risk&#xD;
             assessment questionnaire.&#xD;
&#xD;
         13. Individuals who are living and/or working with severely immunocompromised people,&#xD;
             children under 15 months old or pregnant women.&#xD;
&#xD;
         14. Family history of immunodeficiency and/or personal history of autoimmune disease&#xD;
             (including psoriasis, rheumatoid arthritis, autoimmune thyroid disease).&#xD;
&#xD;
         15. History of type I or type II diabetes mellitus including cases controlled with diet&#xD;
             alone.&#xD;
&#xD;
         16. History or ongoing malignancy.&#xD;
&#xD;
         17. Major congenital defects or serious chronic illness at the time of enrolment.&#xD;
&#xD;
         18. History of serious adverse reactions to vaccine administration, including anaphylaxis&#xD;
             and related symptoms, such as urticaria, respiratory difficulty, angioedema and&#xD;
             abdominal pain to vaccines, or history of allergic reaction likely to be exacerbated&#xD;
             by any component of the vaccine.&#xD;
&#xD;
         19. Acute or chronic, clinically significant, as determined by the investigator,&#xD;
             pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by&#xD;
             physical examination or laboratory screening tests.&#xD;
&#xD;
         20. Individuals whose Body Mass index (BMI) is less than 18.5 or greater than 30 (i.e.&#xD;
             underweight or obese).&#xD;
&#xD;
         21. History of clinically significant, as determined by the investigator, neurological&#xD;
             disorder or seizures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>27 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert - Leroux-Roels, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geert.lerouxRoels@UGent.be</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gent University &amp; Hospital, Center for Vaccinology</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>March 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <last_update_submitted>February 13, 2012</last_update_submitted>
  <last_update_submitted_qc>February 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 27, 2013</submitted>
    <returned>July 24, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

